IMV Inc. (IMV) Reports Q1 Loss of $0.10

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. RXRX

Go back to IMV Inc. (IMV) Reports Q1 Loss of $0.10

IMV Inc. (IMV) Announces Dr. Michael Kalos to Board

May 11, 2021 7:15 AM EDT

IMV Inc. (NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced the appointment of Dr. Michael Kalos, to its board of directors effective today. Dr. Kalos is an internationally recognized expert in T cell therapy and immunotherapy and brings over 25 years of experience from both industry and academia. His previous career highlights include serving as Vice President of Immuno-oncology and Oncology Cell Therapies at Janssen and as Chief Scientific Officer of Immuno-Oncology at Eli Lilly.

We are enthusiastic to add such an experienced scientist and industry... More